Literature DB >> 10595432

Altered adaptive behaviour expressed in an open-field paradigm in experimental hepatic encephalopathy.

G Apelqvist1, B Hindfelt, G Andersson, F Bengtsson.   

Abstract

Chronic hepatic encephalopathy (HE) encounters a neuropsychiatric syndrome arising as a complication to liver dysfunction. Patients with chronic HE display a great variety of neuropsychiatric symptoms including such mental derangements as adaptational difficulty, and deteriorated learning and memory capacity. The portacaval shunt (PCS) in the rat is a widely used model for experimental chronic HE. In the present study, the adaptive capacity of unhabituated PCS rats and sham-operated control rats were studied by measuring two exploratory behaviours (locomotion and rearing) during 5 or 60 min, at four consecutive days or nights with 24 h between sessions. The results revealed that PCS and sham-operated control rats showed parallel behavioural outcome over the four sessions in the 5-min trial. However, at the four consecutive test sessions in the 60-min trials, the sham-controls displayed a continuing decrease in overall activity between sessions whereas the PCS rats evidenced a repeated and stable activity level. These results indicate a presence of a long-term habituation deficiency as exhibited by the PCS rats. Additionally, the results indicate that differences in normal open-field motor behaviour between PCS rats and controls may not be found if such tests are conducted repeatedly during night-time but may emerge when tested repeatedly during daytime. The results may also be interpreted as a possible impaired learning/memory capacity in PCS rats. However, further investigations of how the PCS procedure affects entities of adaptation and learning ability are needed before any conclusions may be drawn since this is the first report of such an impairment in experimental chronic HE when represented by the PCS rat.

Entities:  

Mesh:

Year:  1999        PMID: 10595432     DOI: 10.1016/s0166-4328(99)00104-7

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  6 in total

Review 1.  Contribution of altered signal transduction associated to glutamate receptors in brain to the neurological alterations of hepatic encephalopathy.

Authors:  Vicente Felipo
Journal:  World J Gastroenterol       Date:  2006-12-28       Impact factor: 5.742

2.  Neuroprotective effects of guanosine administration on behavioral, brain activity, neurochemical and redox parameters in a rat model of chronic hepatic encephalopathy.

Authors:  L G Paniz; M E Calcagnotto; P Pandolfo; D G Machado; G F Santos; G Hansel; R F Almeida; R S Bruch; L M Brum; F V Torres; A M de Assis; E P Rico; D O Souza
Journal:  Metab Brain Dis       Date:  2014-05-01       Impact factor: 3.584

Review 3.  Serotonin brain circuits with a focus on hepatic encephalopathy.

Authors:  Violina Lozeva-Thomas
Journal:  Metab Brain Dis       Date:  2004-12       Impact factor: 3.584

4.  Impaired novelty acquisition and synaptic plasticity in congenital hyperammonemia caused by hepatic glutamine synthetase deficiency.

Authors:  Aisa N Chepkova; Olga A Sergeeva; Boris Görg; Helmut L Haas; Nikolaj Klöcker; Dieter Häussinger
Journal:  Sci Rep       Date:  2017-01-09       Impact factor: 4.379

5.  Impairment of the organization of locomotor and exploratory behaviors in bile duct-ligated rats.

Authors:  Renata Leke; Diogo L de Oliveira; Ben Hur M Mussulini; Mery S Pereira; Vanessa Kazlauckas; Guilherme Mazzini; Carolina R Hartmann; Themis R Silveira; Mette Simonsen; Lasse K Bak; Helle S Waagepetersen; Susanne Keiding; Arne Schousboe; Luis V Portela
Journal:  PLoS One       Date:  2012-05-07       Impact factor: 3.240

6.  Pharmacological manipulation of cyclic GMP levels in brain restores learning ability in animal models of hepatic encephalopathy: therapeutic implications.

Authors:  Regina Rodrigo; Pilar Monfort; Omar Cauli; Slaven Erceg; Vicente Felipo
Journal:  Neuropsychiatr Dis Treat       Date:  2006-03       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.